CTRI/2019/10/021627尚未招募未知
A Randomized, Double Blind, Multiple-Dose, Placebo-Controlled, Parallel Group, Multi-center Study toCompare the Efficacy and Safety of Budesonide andFormoterol Fumarate Dihydrate Inhalation Aerosol80/4.5 mcg per Actuation of Deva Holding A.Å? withSymbicort® 80/4.5 INHALATION AEROSOL(delivering Budesonide 80 mcg and FormoterolFumarate Dihydrate 4.5 mcg Per Actuation) in AdultAsthmatics. - NA
Deva Holding AS0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Ba/be
入排标准
入选标准
- •1. Male or female subjects (>= 18 years of age) of non-child bearing potential or of child bearing potential committing to consistent and correct use of an acceptable method of birth control.
- •2. Subjects diagnosed with asthma, as defined by the National Asthma Education and Prevention Program (NAEPP)1, at least 6 months prior to screening.
- •3. Subjects with moderate-to-severe asthma with a pre-bronchodilator FEV1 of >=45% and <=85% of predicted normal, measured at least 6 hours after short-acting β agonist (SABA) and at least 24 hours after the last dose of long-acting β agonist (LABA), at the screening visit and prior to randomization.
- •4. Currently non-smoking; had not used tobacco products (i.e., cigarettes, cigars, pipe tobacco) within the past year, and had <= 10 pack-years of historical use.
- •5. Subjects demonstrating >=15% and >=0.20 L reversibility of FEV1 within 30 minutes following 360 mcg of albuterol inhalation (pMDI) (Note: Subjects who fail to demonstrate the required reversibility at the Screening Visit (Visit 1) are eligible to enter the Run-in Period and repeat the testing a day before randomization).
- •6. Subjects must be stable on their chronic asthma treatment regimen for at least 4 weeks prior to enrollment.
- •7. Subjects must be able to discontinue their asthma medications (inhaled corticosteroids (ICS), leukotriene modifiers (LTM), long-acting β agonists (LABAs), etc.,) during the placebo run-in period and for the remainder of the study. List of prohibited medication during run-in and treatment period is provided in Section 6.5.1.
- •8. Subjects must be able to replace current regularly scheduled short-acting β agonists (SABAs) with salbutamol/albuterol inhaler for use only on an as-needed basis for the duration of the study (subjects should be able to withhold all inhaled SABAs for at least 6 hours prior to lung function assessments on study visits).
- •9. Subject must be able to demonstrate correct use of the metered-dose inhaler (MDI) using the Vitalograph Aerosol Inhalation Monitor.
- •10. Willingness to give their written informed consent to participate in the study.
排除标准
- •1. Institutionalized subjects.
- •2. History of intolerance to aerosolized β2-adrenergic agonists.
- •3. Subjects with life-threatening asthma, defined as a history of asthma episodes(s) requiring intubation, and/or associated with hypercapnoea, respiratory arrest or hypoxic seizures, asthma-related syncopal episodes(s), or hospitalizations within the past year or during the run-in period.
- •4. History of frequent exacerbations in the previous year.
- •5. Subject has a respiratory infection or other viral/bacterial illness, or is recovering from such an illness at the time of baseline visit that, in the investigators opinion, will interfere with the subjects lung function.
- •6. Subjects with clinical visual evidence of candidiasis at the screening visit, in the opinion of the investigator, would put the subject at risk through study participation, or would affect the study analyses if the disease exacerbated during the study.
- •7. Peak expiratory flow must not be below 50% of predicted normal.
- •8. Subjects with significant respiratory disease other than asthma (chronic obstructive pulmonary disease (COPD), interstitial lung disease, etc.).
- •9. Subjects with evidence or history of clinically significant disease or abnormality including congestive heart failure, uncontrolled hypertension, uncontrolled coronary artery disease, myocardial infarction, or cardiac dysrhythmia. In addition, historical or current evidence of significant hematologic, hepatic, neurologic, psychiatric, renal, or other diseases that, in the opinion of the investigator, would put the subject at risk through study participation, or would affect the study analyses if the disease exacerbated during the study.
- •10. Subjects has current clinical evidence of respiratory conditions other than asthma including but not limited to severe nasal polyposis, significant and symptomatic chronic rhinosinusitis,, pneumonia, pneumothorax, atelectasis, bronchiectasis, Churg-Struss Disease, lung resection, pulmonary fibrotic disease, allergic bronchopulmonary aspergillosis, cystic fibrosis, bronchopulmonary dysplasia, chronic obstructive pulmonary disease (COPD), sarcoidosis interstitial lung disease, pulmonary tuberculosis.
- •11. Subjects using prescription or non-prescription medication(s) with the potential to affect the course of asthma or to interact with sympathomimetic amines, e.g.,:
- •- β-blockers
- •- tricyclic antidepressants
- •- monoamine oxidase inhibitors
- •12. Subjects who required systemic corticosteroids (for any reason) within the past 4 weeks.
- •13. Subjects who received a potent CYP3A4 inhibitor within 4 weeks of the screening visit (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin).
- •14. Subjects has clinical significant abnormality in the ECG at the screening visit.
- •15. Hypersensitivity to any sympathomimetic drug (e.g., formoterol or albuterol) or any inhaled, intranasal, or systemic corticosteroid therapy.
- •16. Presence of glaucoma, cataracts, ocular herpes simplex, or current malignancy other than basal cell carcinoma.
- •17. Omalizumab or any other monoclonal or polyclonal antibody therapy taken for any reason within 6 months prior to randomization.
- •18. Inability to tolerate or unwillingness to comply with required washout periods or temporary withdrawal for all applic
研究者
相似试验
进行中（未招募）
不适用
A Randomized, Multiple-dose, Double-Blind, Placebo- and Active-Controlled, Parallel Group Efficacy and Safety Study to determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat Inhaler in Patients with Chronic Obstructive PulmonaryDisease (COPD) -Chronic Obstructive Pulmonary DiseaseEUCTR2005-000650-79-BEBoehringer Ingelheim Coordination Centre Belgium420
进行中（未招募）
不适用
A Randomized, Double-Blind, Multiple Dose, Placebo-Controlled, Parallel Group, 48 Week, Study of Oral Recombinant sCT Compared to Calcitonin Nasal Spray in Postmenopausal Osteoporotic Women - A Comparison of Oral and Nasal Calcitonin in Postmenopausal Osteoporotic WomeMedDRA version: 9.1Level: LLTClassification code 10031285Term: Osteoporosis postmenopausalPostmenopausal OsteoporosisEUCTR2008-003322-42-BGTarsa Therapeutics, Inc.550
进行中（未招募）
不适用
A Randomized, Double-Blind, Multiple Dose, Placebo-Controlled, Parallel Group, 48 Week, Study of Oral Recombinant Calcitonin (rsCT) Compared to Calcitonin Nasal Spray in Postmenopausal Osteoporotic Women - A Comparison of Oral and Nasal Calcitonin in Postmenopausal Osteoporotic WomeMedDRA version: 9.1Level: LLTClassification code 10031285Term: Osteoporosis postmenopausalPostmenopausal OsteoporosisEUCTR2008-003322-42-GBTarsa Therapeutics, Inc.550
进行中（未招募）
不适用
A Randomized, Double-Blind, Multiple Dose, Placebo-Controlled, Parallel Group, 48 Week, Study of Oral Recombinant Calcitonin (rsCT) Compared to Calcitonin Nasal Spray in Postmenopausal Osteoporotic Women - A Comparison of Oral and Nasal Calcitonin in Postmenopausal Osteoporotic WomeMedDRA version: 9.1Level: LLTClassification code 10031285Term: Osteoporosis postmenopausalPostmenopausal OsteoporosisEUCTR2008-003322-42-HUTarsa Therapeutics, Inc.550
进行中（未招募）
1 期
A study to find out more about the effect of AMG 181 in people with moderate to severe ulcerative colitisMedDRA version: 16.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000004856Moderate to severe Ulcerative ColitisEUCTR2011-005251-13-LVAmgen Inc360